The Use of the OMERACT Ultrasound Tenosynovitis Scoring System in Multicenter Clinical Trials

Mads Ammitzbøll-Danielsen, Mikkel Østergaard, Esperanza Naredo, Annamaria Iagnocco, Ingrid Möller, Maria-Antonietta D'Agostino, Frédérique Gandjbakhch, Lene Terslev

7 Citations (Scopus)

Abstract

OBJECTIVE: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design.

METHODS: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system.

RESULTS: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean ≥ 0.8).

CONCLUSION: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.

Original languageEnglish
JournalJournal of Rheumatology
Volume45
Issue number2
Pages (from-to)165-169
Number of pages5
ISSN0315-162X
DOIs
Publication statusPublished - Feb 2018

Fingerprint

Dive into the research topics of 'The Use of the OMERACT Ultrasound Tenosynovitis Scoring System in Multicenter Clinical Trials'. Together they form a unique fingerprint.

Cite this